Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2013
For the nine months, the company reported revenue of $301,000 against of $675,000 for the corresponding period ended November 30, 2012. Adjusted LBITDA was $4,607,000 against of $3,024,000 in the corresponding prior-year period. Net loss was $9,059,000 or $0.12 per share was recorded for the nine-month period ended November 30, 2013, against a net loss of $4,940,000 or $0.07 per share in the corresponding prior-year period.